Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | USP10 | Q14694 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5361674 | 0.86 | SMN1; SMN2 (0.44) | LMNAALDH1A1MAPTPLA2G2ASMN1; SMN2 | |
| SCHEMBL14351241 | 0.84 | LTA4H (0.46) | ALDH1A1ACHETSHRTP53 | |
| SCHEMBL5358366 | 0.83 | PPARG (0.43) | — | |
| SCHEMBL5353654 | 0.80 | LMNA (0.55) | LMNAALDH1A1ACHEMAPTPLA2G2A | |
| SCHEMBL2007973 | 0.74 | LMNA (0.55) | LMNAALDH1A1ACHEMAPTPLA2G2A | |
| SCHEMBL5361237 | 0.72 | ALDH1A1 (0.52) | LMNAALDH1A1MAPTSMN1; SMN2TSHR | |
| SCHEMBL2005437 | 0.71 | LMNA (0.53) | LMNAALDH1A1ACHEMAPTPLA2G2A | |
| SCHEMBL2002080 | 0.71 | LMNA (0.53) | LMNAALDH1A1ACHEMAPTPLA2G2A | |
| SCHEMBL14351228 | 0.70 | CYP19A1 (0.35) | ACHEMAPTTP53CYP19A1 | |
| SCHEMBL5323957 | 0.70 | LMNA (0.53) | LMNAALDH1A1ACHEMAPTPLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070287699-A1 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| US-20070287699-A1 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| WO-2007130499-A2 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287699-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | LMNA 4460/4885ALDH1A1 1759/4885ACHE 4607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.